Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomet progresses in Japan; CardioDynamics moves into profit

This article was originally published in Clinica

Executive Summary

Orthopaedic company Biomet's sales increase was led by "strong, balanced growth in its reconstructive, fixation and spinal product lines", the company says. Excluding foreign currency effects, growth in the quarter was 21%. The company, of Warsaw, Indiana, is continuing to make progress in establishing direct sales operations in Japan. However, its sales were hit by an estimated $1.7 million reduction in product purchases by its former distribution organisation in Japan. "However, we believe that Biomet's long-term prospects in Japan will improve as a result of these initiatives," said Dane Miller, Biomet's president and CEO. The company's reconstructive device division saw sales rise by 16% to $161 million, led by demand for total knee implants. Sales in the fixation division increased by 16% to $54 million, driven by its electrical stimulation systems. Spinal sales were $27 million, a 107% increase, while sales of other products were up 14% to $30 million.

You may also be interested in...

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts